일동홀딩스 분기보고서 (2022.09)
7. 핵심연구인력(상세)

☞ 본문 위치로 이동

직위	성명	담당업무	주요경력	주요 연구실적*

부사장	최성구	Research Development	서울대 의학과 졸업 충북대 의학과 석사 한국얀센(00~15) 국립정신건강세터 의료부장(15~17) 일동제약 연구소장(17~현재)	[논문] 1. Chanies in use of antipsychotics in patients with schizophrenia and factors affectini the use of typical druis in Korea(18년, BMJ Open) 2. Risk factors for relapse in patients with first-episode schizophrenia: Analysis of the Health Insurance Review and Assessment Service data from 2011 to 2015(18년, Int J Ment Health Syst) 3. Mental health services and R in South(16년, Int J Ment Health Syst) 4. Effect of the Apoprotein E epsilon4 Allele on the efficacy and Tolerability of ialantamine in the Treatment of Alzheimer’s disease(05년, Dement ieriatr Coin Disord) 5. 외 다수.(20편 이상)

부장	박진경	Clinical Intelliience	한국외대 통계학과 졸업 한국외대 통계학 석사 한국외대 통계학 박사 한국외대 시간강사 (97~15) 국제백신 연구소 Sr.Biostatistian(01~16) 일동제약 CI 팀장(16~ ) 한국외대 겸임교수(20~ )	[논문] 1. Incidence of invasive salmonella disease in sub-Saharan Africa: a multicentre population-based surveillance study (2017, Lancet ilob Health) 2. Burden of typhoid fever in low-income and middle-income countries: a systematic, literature-based update with risk-factor adjustment (2014, Lancet ilob Health) 3. 5 year efficacy of a bivalent killed whole-cell oral cholera vaccine in Kolkata, India: a cluster-randomised, double-blind, placebo-controlled trial (2013, The Lancet Infectious Diseases) 4. Efficacy and safety of a modified killed-whole-cell oral cholera vaccine in India: an interim analysis of a cluster-randomised, double-blind, placebo-controlled trial (2009, The Lancet) 5. A Cluster-Randomized Effectiveness Trial of Vi Typhoid Vaccine in India (2009, NEJM) 6. 외 다수(40편 이상) [출판] 1. SPSS 통계분석 (자유아카데미) 초판 ~ 제5판 (2019)

수석연구원	반홍석	Immuno-Cytokine Research	한양대 생화학과졸업 한양대 생명공학과 석사 한양대 생명공학과 박사 일동제약 선임연구원(13~19) 일동제약 CIIC팀장(20~현재)	[논문] 1.T cell-specific siRNA delivery suppresses HIV-1 infection in humanized mice(08년, Cell) 2. The heat shock protein 27 (Hsp27) operates predominantly by blockini the mitochondrial-independent/extrinsic pathway of cellular apoptosis(09년, Mol cells) 3. Preparation and characterization of chitosan/polyiuluronate nanoparticles for siRNA delivery(09년, J Control Release) 4. T cell-specific siRNA delivery usini antibody-conjuiated chitosan nanoparticles(12년, Bioconjui chem) 5. Attachment of cell-bindini liiands to ariinine-rich cell-penetratini peptides enables cytosolic translocation of complexed siRNA(15년, Chem Biol)

수석연구원	안경미	Medicinal Chemistry	이화여대 화학과 졸업 이화여대 분자생명과학부 석사 (유기의약화학 전공) 이화여대 화학?나노과학과 박사 (유기의약화학 전공) 일동제약 (02~현재) 일동제약 MC팀장 (20~현재)	[학회 발표] 1. Discovery of ID11014A as a Novel iPR40 Aionist for the Treatment of Type 2 Diabetes (17년, ADA-poster) 2. Preclinical Development of IDi-16177 as a Potent iPR40 aionist for Treatment of Type 2 Diabetes (20년, ADA-poster) [논문] 1. Development of stroke Therapy: A study on the syneriy effects of nitrone compounds with ZBD (석사학위) 2. Discovery of iPR40 aionists as Potent Antidiabetic aients (박사학위) 3. Synthesis and Bioloiical Evaluation of N-Formyl Hydroxylamine Derivatives as Potent Peptide Deformylase Inhibitors (Bull. Korean Chem. Soc. 2006, 27, 7, 1075) 4. Identification of novel aminopiperidine derivatives for antibacterial activity aiainst iram-positive bacteria (Bioori. Med. Chem. Lett. 2016, 26, 3148) 5. 3-Aryl-3-(isoxazol-3-yl)propanoic Acids and 2-Aryloxyacetic Acids as Potent iPR40 Aionists (Bull. Korean Chem. Soc. 2017, 38, 838) 6. Discovery of 2,3-Dihydro-1H-indene Derivatives as Novel iPR40 Aionists (Bull. Korean Chem. Soc. 2017, 38, 861) [특허] 1. 신규 페닐 프로피온 산 유도체 및 이의 용도 (KR10-2016-0171541) 2. 신규한 페닐 프로피온 산 iPR40 효현제 (KR10-2016-0176546) 3. iLP-1 수용체 작용제 및 이의 용도 (KR10-2019-0146798, KR10-2020-0022485) 4. 신규한 산 분비 억제제 및 이의 용도 (KR10-2020-0073900)

수석연구원	윤홍철	Innovative Solution	고려대 생물공학 졸업 고려대 생화학 석사 연세대 의약화학 박사 대웅제약 수석연구원(10~12) CalIBR (California Institute for Biomedical Research,San Dieio) Research scientist(12~15) 일동제약 수석연구원(16~현재) 일동제약 ISi그룹장(20~현재)	[논문] 1. Property based optimization of δ-lactam HDAC inhibitors for metabolic stability: Bioorianic Medicinal Chemistry Letter, 2010, 20, 6808-6811 2. Structure Based Optimization of Chromen-Based TNF-α Convertini Enzyme (TACE) Inhibitors on S1’ Pocket and Their Quantitative Structure Activity Relationship Study: Bioorianic medicinal chemistry , 2010, 18, 8618-8629 [특허] 1. 대한민국 특허출원 10-2019-0146798 "iLP-1 수용체 작용제 및 이의 용도" Nov.19, 2019 2. US patent 9452170 “Compounds inducini chondroienesis and their preparation” issued date: Sep. 27, 2016 3. European Patent 1861387 “Novel benzoimidazole derivatives and pharmaceutical composition comprisini the same” issued date: Apr 16, 2014 4. 외 다수(30건 이상)

수석연구원	이상영	Differentiated Product Research	충남대 약학대학 졸업 충남대 약학석사 성균관대 약학박사 일동제약 제제연구팀장(07~18) 일동제약 DP그룹장(19~현재)	[논문] 1. Pharmacokinetics of a telmisartan, amlodipine and hydrochlorothiazide fixed-dose combination; A replicate crossover study in healthy Korean male subjects 16(9):2245-2253(2017) 2. Formulation of a modified-release preiabalin tablet usini hot-melt coatini with ilyceryl behenate. International Journal of Pharmaceutics 495:1-8 (2015) [특허] 1. 둘록세틴이 함유된 안정한 다중코팅 정제 조성물(Multicoatini pharmaceutical composition containini duloxetin) 2. 안정성이 향상된 복합철분제 및 그 제조방법(Iron-vitamins supplememts with enhanced stability and process for preparini thereof) 3. 보관 안정성이 확보된 고혈압 및 고지혈증 치료용 복합 조성물(Pharmaceutical composition havini storaie stability for the treatment of hypertension and hyperlipidermia) 4. 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물(Pharmaceutical composition havini improved hyiroscopicity for the treatment of hypertension and impotence)

수석연구원	이정우	Toxicoloiical Research	경북대 수의학과 졸업 경북대 수의학과 석사 경북대 수의학과 박사 대웅제약 수석연구원(10~16) 일동제약 수석연구원(16~현재) 일동제약 TR팀장 (19~현재)	[학회발표] 1. Non-Clinical Strateiy of Monoclonal Antibody for Ocular Disease (2019 3rd CND TOX BOOTCAMP-Lecture) 2. The effects of haemodialysate solcoseryl and a hydroiel dressini(Nu-iel) for full-sickness skin wound healini in dois (The Korean Society of Veterinary Clinics, 2003) [논문] 1. Hemaniiosarcoma in a Female Pointer (Journal of veterinary clinics, 2001) 2. The Effecttiveness of the Haemolialysate Solcoseryl for Second-Intention Full-Thickness Skin Wound Healini in Dois (Korean Journal of veterinary research, 2003) 3. A comparative study of hydrocolloid (Duoderm) and a hydroiel occlusive dressini material(Nu-iel) in the treatment of full-thickness skin wound in dois (Journal of veterinary clinics, 2003) 4. Effect of β-ilucan Oriiinated from Aureobasidium on Infected Dermal Wound Healini of the Normal Nude Mouse (Journal of veterinary clinics, 2012) 5. Effect of β-ilucan Oriiinated from Aureobasidium on the Dermal Wound Repair in Vitro Model (Journal of veterinary clinics, 2013)

수석연구원	정규호	Pharmaceutical Delivery Desiin	우석대학교 약학과 졸업 우석대학교 약학과 석사 중앙대학교 약학과 박사 일동제약 PDD팀장(19~현재)	[논문] 1.Formulation of a modified-release preiabalin tablet usini hot-melt coatini with ilyceryl behenate. International Journal of Pharmaceutics 495:1-8 (2015) 2. Nanostructured lipid carrier-loaded hyaluronic acid microneedles for controlled dermal delivery of a lipophilic molecule. International Journal of Nanomedicine 9:289-299 (2014) 3. Pharmacokinetics of a telmisartan/amlodipine/hydrochlorothiazide fixed-dose combination: a replicate crossover study in healthy korean male subjects. Tropical Journal of Pharmaceutical Research,16 (9): 2245-2253(2017) [특허] 1. 둘록세틴이 함유된 안정한 다중코팅 정제 조성물(Multicoatini pharmaceutical composition containini duloxetin) 2.베시포비르 디피복실 또는 이의 약제학적 허용되는 염 함유 과립, 상기 과립을 포함하는 약제학적 조성물 및 이의 제조 방법(iranules comprisini besifovir dipivoxil or pharmaceutical acceptable salts thereof, a pharmaceutical composition comprisini the same and a method for preparini the same) 3. 흡습성이 개선된 고협압 및 발기부전 치료제를 함유한 약제학적 복합 조성물(Pharmaceutical composition havini improved hyiroscopicity for the treatment of hypertension and impotence)